FDA Creates Exclusivity Board To Help Resolve Vexing Questions
The board, housed within CDER, seeks to assure FDA makes consistent decisions on new chemical entity, new clinical trial and biologics exclusivity; FDA denied GSK’s request for NCE exclusivity for Veramyst and revoked Pfizer’s Torisel exclusivity.